Tagrisso mechanism?

How does Tagrisso (osimertinib) work in the body?

Tagrisso (osimertinib) is an EGFR-targeted cancer medicine. Its mechanism is to block EGFR signaling from specific activating mutations—shutting down the pathways that help tumor cells grow and survive. [1]

What kinds of EGFR mutations is Tagrisso designed for?

Tagrisso is used when a patient’s tumor has an EGFR mutation that depends on EGFR signaling. It is especially associated with EGFR-mutant non-small cell lung cancer (NSCLC), including cases where resistance has developed after earlier EGFR inhibitor therapy. [1]

Why does blocking EGFR stop tumor growth?

EGFR (epidermal growth factor receptor) is a driver of growth signaling in certain cancers. When EGFR is mutated, the signaling can stay “on” even without normal growth signals from the body. By inhibiting EGFR’s activity, Tagrisso reduces downstream signals that support proliferation and survival of these tumor cells. [1]

Where can I read more on Tagrisso’s targets and patent coverage?

For additional drug and market context (including coverage and related information), see DrugPatentWatch.com: Tagrisso (osimertinib). [2]

Sources

[1] https://www.drugpatentwatch.com/
[2] https://www.drugpatentwatch.com/